International Circulation:  When we talk about a particular combination， like with the valsartan and amlodipine combination what is the particular advantage here when we combine and valsartan together with an amlodipine， what is the added benefit specifically clinically for clinicians? 

国际循环：缬沙坦和氨氯地平联合对临床或临床医生有无额外益处？

Dahlof: I mean for clinicians I think that clinicians want a simple broadly applicable tool to improve on their patients health and welfare and in particular improve control of the blood pressure because I think that many physicians really think that it is important.  But when they use different mono therapies than they use this kind of approach they do not succeed so often so I think that by providing a tool like an ARB plus a CCB and valsartan and amlodipine is a very good example of that because it is available in many countries， you provide a tool that can give 80% of patients control of blood pressure so I think that this gives the doctors the confidence to tell the patients that ‘I can help you with this’ if they talk about mono therapy they can not give that confidence， they will say ‘ok if this does not work， you have to come back and we have another one you can switch to’.  I think the combination therapy really improves on the patient doctor relationship as well.

Dahlof：我认为临床医生需要简明、可普遍推广的方案来改善患者的健康和福利状况，尤其是改善血压，很多医生都以此为首要目的。但若选择与此不同的单一疗法常无法达到相似的疗效，因此提供类似ARB联合CCB、缬沙坦联合氨氯地平这样的治疗方案可为许多国家提供良好的范例，它使80%的患者血压得到控制，让医生可以自信的对患者说我可以用它帮助你。而单一疗法不能给他们这种信心，医生只能说“好吧，如果这种疗法不奏效，你需要回来尝试另一种。”联合疗法确实改善了医患关系。